Global Markets Direct’s pharmaceuticals report, “Theravance, Inc. - Product Pipeline Review - 2013” provides data on the Theravance, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Theravance, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Theravance, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.
- Theravance, Inc. - Brief Theravance, Inc. overview including business description, key information and facts, and its locations and subsidiaries. - Review of current pipeline of Theravance, Inc. human therapeutic division. - Overview of pipeline therapeutics across various therapy areas. - Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe. - Product profiles for late stage and clinical stage products of Theravance, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones. - Recent updates of the Theravance, Inc.’s pipeline in the last quarter. - Key discontinued and dormant projects. - Latest news and deals relating to the products.
Reasons to buy
- Evaluate Theravance, Inc.’s strategic position with total access to detailed information on its product pipeline. - Assess the growth potential of Theravance, Inc. in its therapy areas of focus. - Identify new drug targets and therapeutic classes in the Theravance, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas. - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps. - Exploit collaboration and partnership opportunities with Theravance, Inc.. - Avoid Intellectual Property Rights related issues. - Explore the dormant and discontinued projects of Theravance, Inc. and identify potential opportunities in those areas.
Table Of Contents
Theravance, Inc. - Product Pipeline Review - 2013 Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Theravance, Inc. Snapshot 5 Theravance, Inc. Overview 5 Key Information 5 Key Facts 5 Theravance, Inc. - Research and Development Overview 6 Key Therapeutic Areas 6 Theravance, Inc. - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Theravance, Inc. - Pipeline Products Glance 11 Theravance, Inc. Clinical Stage Pipeline Products 11 Phase II Products/Combination Treatment Modalities 11 Phase I Products/Combination Treatment Modalities 12 Theravance, Inc. - Early Stage Pipeline Products 13 Preclinical Products/Combination Treatment Modalities 13 Discovery Products/Combination Treatment Modalities 14 Theravance, Inc. - Drug Profiles 15 Compound-39b 15 Product Description 15 Mechanism of Action 15 RandD Progress 15 TD-1211 16 Product Description 16 Mechanism of Action 16 RandD Progress 16 TD-1607 17 Product Description 17 Mechanism of Action 17 RandD Progress 17 TD-1792 18 Product Description 18 Mechanism of Action 18 RandD Progress 18 TD-2872 19 Product Description 19 Mechanism of Action 19 RandD Progress 19 TD-4208 20 Product Description 20 Mechanism of Action 20 RandD Progress 20 TD-8954 21 Product Description 21 Mechanism of Action 21 RandD Progress 21 TD-9855 22 Product Description 22 Mechanism of Action 22 RandD Progress 22 telavancin hydrochloride 23 Product Description 23 Mechanism of Action 23 RandD Progress 23 THRX-198321 24 Product Description 24 Mechanism of Action 24 RandD Progress 24 THRX-200495 25 Product Description 25 Mechanism of Action 25 RandD Progress 25 velusetrag 26 Product Description 26 Mechanism of Action 26 RandD Progress 26 Theravance, Inc. - Pipeline Analysis 27 Theravance, Inc. - Pipeline Products by Therapeutic Class 27 Theravance, Inc. - Pipeline Products By Target 29 Theravance, Inc. - Pipeline Products by Route of Administration 30 Theravance, Inc. - Pipeline Products By Mechanism of Action 31 Theravance, Inc. - Recent Pipeline Updates 33 Theravance, Inc. - Dormant Projects 37 Theravance, Inc. - Discontinued Pipeline Products 38 Discontinued Pipeline Product Profiles 38 TD-6301 38 Theravance, Inc. - Locations And Subsidiaries 39 Head Office 39 Appendix 40 Methodology 40 Coverage 40 Secondary Research 40 Primary Research 40 Expert Panel Validation 40 Contact Us 41 Disclaimer 41
List of Tables
Theravance, Inc., Key Information 5 Theravance, Inc., Key Facts 5 Theravance, Inc. - Pipeline by Indication, 2013 8 Theravance, Inc. - Pipeline by Stage of Development, 2013 9 Theravance, Inc. - Monotherapy Products in Pipeline, 2013 10 Theravance, Inc. - Phase II, 2013 11 Theravance, Inc. - Phase I, 2013 12 Theravance, Inc. - Preclinical, 2013 13 Theravance, Inc. - Discovery, 2013 14 Theravance, Inc. - Pipeline By Therapeutic Class, 2013 28 Theravance, Inc. - Pipeline By Target, 2013 29 Theravance, Inc. - Pipeline By Route of Administration, 2013 30 Theravance, Inc. - Pipeline Products By Mechanism of Action, 2013 32 Theravance, Inc. - Recent Pipeline Updates, 2013 33 Theravance, Inc. - Dormant Developmental Projects,2013 37 Theravance, Inc. - Discontinued Pipeline Products, 2013 38
List of Figures
Theravance, Inc. - Pipeline by Indication, 2013 7 Theravance, Inc. - Pipeline by Stage of Development, 2013 9 Theravance, Inc. - Monotherapy Products in Pipeline, 2013 10 Theravance, Inc. - Pipeline By Therapeutic Class, 2013 27 Theravance, Inc. - Pipeline By Route of Administration, 2013 30 Theravance, Inc. - Pipeline Products By Mechanism of Action, 2013 31